The Challenge
A WHO-GMP and US-FDA approved parenteral drug manufacturer in Ahmedabad produces sterile injectables in vials — antibiotics, oncology drugs, and IV preparations — for domestic and US market supply. Flip-off seals (aluminium crimp shells with polypropylene buttons) are the primary container closure component for their glass vials. As a critical packaging component for parenteral products, flip-off seal quality is subject to strict pharmacopoeial and FDA requirements.
The manufacturer's existing flip-off seal inspection was manual: quality inspectors examined seals under a magnifying lens at 600 caps per minute — physically impossible to inspect every seal, so AQL sampling was applied. The process had three critical weaknesses identified during an FDA PAI (Pre-Approval Inspection) for a new ANDA submission:
1) No validated 100% inspection method. 2) Inspection records were handwritten on paper log sheets — not 21 CFR Part 11 compliant. 3) No mechanism to segregate rejected seals before the crimping station, creating a risk of defective seals being crimped onto vials.
The FDA inspector issued an Observation under 21 CFR 211.68 (electronic records) and 21 CFR 211.84 (testing of components) — requiring 100% automated inspection with compliant electronic records as a condition of ANDA approval. The pending ANDA represented projected revenue of ₹18 crore per year from the US market.
The Solution
Optomech installed the FOSIS (Flip-Off Seal Inspection System) configured for 13 mm and 20 mm seal sizes — the two formats used for the ANDA products. The FOSIS uses a stainless-steel vibratory bowl feeder to orient seals and present them to multiple high-resolution camera stations in a controlled, repeatable sequence. Each seal is inspected across its full top surface, band, and side profile at 600 seals per minute — matching the speed of the downstream crimping equipment exactly.
The defect detection library was configured to identify: cuts in the aluminium shell and PP button; wrinkles and deformations; missing or misaligned PP caps; black marks and surface contamination; ring separation; shell intermixing between seal sizes; colour shade inconsistencies; and short-fill or incomplete-mould conditions. Defective seals are automatically diverted to a rejection accumulator before reaching the crimping station — eliminating the risk of a defective seal being crimped onto a vial.
The FOSIS software is built for 21 CFR Part 11 compliance: all inspection data, rejection events, tolerance settings, and system configuration changes are logged with electronic signature, timestamp, and user ID in an audit trail that cannot be altered without a new audit entry. Batch inspection reports are generated automatically in PDF format with full traceability. The 3-level password access system enforces role-based control — operators can run the system but cannot modify acceptance criteria without QA authorisation and documented electronic signature.
21 CFR Part 11 Compliance Features
Defects Detected by the System
Results Achieved
| Metric | Result |
|---|---|
| FDA ANDA approval | ANDA approved — FDA 21 CFR Part 11 observation closed; US market entry achieved |
| Inspection coverage | 100% of all flip-off seals inspected before crimping at 600 seals/min |
| 21 CFR Part 11 compliance | Full audit trail, electronic signatures, user-role control — accepted by FDA |
| Defective seals detected | Avg. 880 defective seals per production day identified and quarantined before use |
| Crimping station risk | Zero defective seals reaching the crimping station — confirmed in process validation |
| Batch record generation | Automated PDF batch inspection reports replacing all paper log sheets |
| Sizes supported | 13 mm and 20 mm seals — changeover in under 15 minutes with stored product recipes |
| Revenue impact | ₹18 crore/year US market revenue unlocked following ANDA approval |
"The FDA observation on our flip-off seal inspection was blocking our ANDA approval — and ₹18 crore a year in US market revenue. The FOSIS gave us 100% inspection, 21 CFR Part 11 compliant records, and a crimping-station rejection gate in one system. We presented the validation data and the audit trail to FDA. The observation was closed at the next review cycle. Optomech understood exactly what was needed for a regulated injectable environment."— Vice President – Regulatory Affairs & Quality, Injectable Drug Manufacturer, Ahmedabad
FDA observation on your flip-off seal inspection process?
FOSIS delivers 100% inspection, 21 CFR Part 11 audit trail, and IQ/OQ/PQ validation in one system. Share your seal format and compliance requirement — we'll propose a solution.